Article Text

SAT0530 Methotrexate for Maintenance of Remission in IgG4-Related Disease
  1. E. Della Torre1,2,
  2. C. Campochiaro2,
  3. G. Ramirez2,
  4. A. Berti2,
  5. M. Lanzillotta1,
  6. E. Bozzolo2,
  7. L. Dagna2,
  8. M.G. Sabbadini1
  1. 1Universita Vita-Salute San Raffaele
  2. 2Unit of Medicine and Clinical Immunology, San Raffaele Scientific Institute, Milano, Italy


Background IgG4-related disease (IgG4-RD) is a relapsing-remitting fibro-inflammatory disorder that dramatically responds to corticosteroids but oftentimes relapses while tapering these medications. Corticosteroid refractoriness appears to be more common in patients with extrapancreatic disease. Experience with disease-modifying antirheumatic drugs as steroid-sparing agents is lacking.

Objectives We aimed to assess the efficacy of methotrexate (MTX) in maintaining steroid-induced remission of IgG4-RD with systemic involvement.

Methods The present study included 10 subjects with biopsy proven IgG4-RD followed between January 2008 and May 2014. At IgG4-RD relapse MTX (up to 20 mg/week) was added to conventional steroid therapy. Efficacy of MTX in maintaining steroid induced remission was assessed at 6 and 12 months by (i) IgG4-RD Responder Index (IgG4-RD RI), (ii) patient's ability to taper or stop prednisone, (iii) total IgG and IgG subclasses, and (iv) radiological imaging. An improvement of the IgG4-RD RI of more than 2 points and an overall IgG4-RD RI <3 after therapy defined partial (PR) and complete (CR) remission, respectively. Paired t-test was used to compare variables at disease relapse, 6 and 12 months after MTX introduction. A p value <0.05 was considered statistically significant.

Results Patients' cohort included 5 males and 5 females, with a mean age of 65 years at the time of diagnosis (range 51 – 75 years). Organ involvement included pancreas, biliary tree, aorta, salivary glands (submandibular and parotid), lacrimal glands, lymph nodes, pachymeninges and retroperitoneum. IgG4-RD relapse occurred on average 7 months (range 2-10 months) after the diagnosis, at a mean steroid daily dosage of 9.6 mg (range 0-20 mg). The mean IgG4-RD RI and serum IgG4 concentration at disease relapse were 8.5 (range 3-15) and 666 mg/dL (range 46-2500 mg/dL), respectively. Oral prednisone at a starting dose of 1mg/kg for 3 weeks induced CR in 4 patients and PR in 6. After 3 weeks of prednisone, the mean IgG4-RD RI, serum IgG4 level, and daily dosage of prednisone were 2.75 (range 1-6), 513 mg/dL (19-1500 mg/dL) and 5 mg (range 0-10 mg), respectively (p value <0.05 for all variables when compared to their values at disease relapse). MTX was introduced on average 5 weeks (range 1-16 weeks) after initiation of corticosteroid therapy and escalated to a dosage of 20 mg/week. The mean daily dosage of prednisone at the time of MTX introduction was 20.75 mg (range 10-50 mg). Six months after MTX introduction 3 patients in CR were able to stop glucocorticoid treatment. Twelve months after MTX initiation, 5 patients were in CR without prednisone; 5 were in PR on prednisone 5 mg/day. No relapses occurred under MTX.

Conclusions Treatment with methotrexate represents a promising strategy for maintaining steroid-induced remission in patients with IgG4-RD.


  1. Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol 2011;23(1):67-71.

Acknowledgements The authors thanks Prof John H Stone from the Massachusetts General Hospital (Boston) for the helpful inputs.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.